Anticancer agent 260

• UNSPSC Description:

  Anticancer agent 260 (Compound 3g/4d) is an orally active anticancer agent, that inhibits the proliferation of cancer cell HCT-116, MIA-PaCa2 and MDA-MB231 with IC50s of 98.7, 81.0, and 77.2 µg/mL, respectively. Anticancer agent 260 exhibits promotes ulcer formation and lipid peroxidation, anti-inflammatory and analgesic efficacy[1][2].

• Target Antigen:

  Reactive Oxygen Species

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

• Field of Research:

  Cancer; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/anticancer-agent-260.html

• Smiles:

  CC1=C(C=CC=C1)C2=NN=C(C3=CC=NC=C3)O2

• Molecular Weight:

  237.26

• References & Citations:

  [1]Gilani SJ, et al., Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole and 1,3,4-oxadiazole derivatives of isoniazid. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4762-5. |[2]Mutchu B R, et al. Bi (OTf) 3 PROMOTED MICROWAVE SYNTHESIS OF 2-ARYL, 5-SUBSTITUTED 1, 3, 4-OXADIAZOLES AND EVALUATION OF THEIR ANTICANCER ACTIVITY[J]. organic synthesis, 2019, 12(4): 2052-2057.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  9007-83-4